





# INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No. 09/446,276

		ABSTRACT--"Pharmacokinetics and bioavailability of papaverine HCl after intravenous, intracorporeal and penis topical administration in beagle dogs." Methods Find Exp Clin Pharmacol 1992 Jun; 14(5): 373-8
		ABSTRACT--"Enhanced absorption of bumetanide from suppositories containing weak acids in rabbits." Biol Pharm Bull 1993 Mar; 16(3): 263-7
		ABSTRACT--"Studies on the nasal absorption of gentamycin." Chung Hua Erh Pi Yen Hou Ko Tsa Chih 1994; 29(3): 134-6
		ABSTRACT--"Pharmacokinetics and endometrial effects of vaginal administration of micronized progesterone in an oil-based solution to postmenopausal women." Fertil Steril 1996 Apr; 65(4): 860-2
		ABSTRACT--"Colonic mucus, smoking and ulcerative colitis." Ann R Coll Surg Engl 1996 Mar; 78(2): 85-91
		ABSTRACT--"Studies on the response of nitroglycerin oral spray compared with sublingual tablets for angina pectoris patients with dry mouth. A multicenter trial." Arzneimittelforschung 1997 Feb; 47(2): 128-31
		ABSTRACT--"Oral transmucosal fentanyl citrate: randomized, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients." J Natl Cancer Inst 1998 Apr 15; 90(8): 611-6
EXAMINER: 		DATE CONSIDERED: 6/11/01
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not-considered. Include copy of this form with next communication.		

<b>Form PTO-1449</b> (Rev. 2-32)		<b>U.S. Department of Commerce</b> <b>Patent &amp; Trademark Office</b>		Atty. Docket No. Q57234	Serial No.: 09/446,276		
<b>INFORMATION DISCLOSURE STATEMENT</b> (Use several sheets if necessary)				Applicant: Yoshihisa NISHIBE, et al.			
				Filing Date: December 21, 1999	Group: 1615		
<b>U.S. PATENT DOCUMENTS</b>							
Examiner Initial		Document Number	Date	Name	Class	Sub-Class	Filing Date (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>							
		Document	Date	Country	Class	Sub-class	Translation Yes/No
		88106305	4/20/99	Japan			Yes
		WO 92/14473	9/3/92	WIPO			Yes
		WO 97/01337	1/16/97	WIPO			Yes
		RU 112102979	11/27/98	Russia			No
		11829	12/22/00	Russia			No
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>							
		ABSTRACT--"Nasal absorption of propranolol from different dosage forms by rats and dogs" J Pharm Sci 1980 Dec; 69(12): 1411-3					
		ABSTRACT--"Nasal absorption of testosterone in rats" J Pharm Sci 1984 Sep; 73(9): 1300-1					
		ABSTRACT--"The time of onset of action of sublingual nitroglycerin in exercise-induced angina pectoris. A methodological study" Eur Hear J 1985 Jul; 6(7): 625-30					
		ABSTRACT--"Intranasal delivery of nicardipine in the rat" J Pharm Sci 1986 Jan; 75(1): 44-6					
		ABSTRACT--"Comparison of the metabolism of diltiazem following percutaneous, subcutaneous, oral and intravenous administration." Drug Des Deliv 1986 Nov; 1(2): 151-6					
		ABSTRACT--"Comparison of bioavailability in man of tamoxifen after oral and rectal administration" J Pharm Pharmacol 1986 Dec; 38(12): 888-92					
		ABSTRACT--"Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects." J Clin Pharmacol 1987 Sep; 27(9): 647-53					
		ABSTRACT--"Pharmacodynamics of acute intranasal administration of verapamil: comparison with i.v. and oral administration." Biopharm Drug Dispos 1985 Oct-Dec; 6(4): 447-54					
		ABSTRACT--"Absolute bioavailability of hydromorphone after peroral and rectal administration in humans: saliva/plasma ratio and clinical effects." J Clin Pharmacol 1987 Sep; 27(9): 647-53					
		ABSTRACT--"Pharmacokinetics of hydromorphone after intravenous, peroral and rectal administration to human subjects." Biopharm Drug Dispos 1988 Mar-Apr; 9(2): 187-99					
		ABSTRACT--"Pharmacokinetics of bioavailability of hydromorphone: effect of various routes of administration." Pharm Res 1988 Nov; 5(11): 718-21					
		ABSTRACT--"Nasal absorption of 17 alpha-ethinyloestradiol in the rat." J Pharm Pharmacol 1989 Mar; 41(3): 214-5					
		ABSTRACT--"Nasal absorption of tetraethylammonium in rats." Arch Int Pharmacodyn Ther 1989 Nov-Dec; 302: 7-17					
		ABSTRACT--"Pharmacokinetic study of neostigmine after intranasal and intravenous administration in the guinea pig." Drugs Exp Clin Res 1990; 16(11): 575-9					
		ABSTRACT--"Asthma therapy: present trends and future prospects." Compr Ther 1990 Mar; 16(3):12-6					
		ABSTRACT--"Transdermal nitroglycerin systems: methods for comparison." Clin Ther 1991 May-Jun; 13(3): 361-7					
		ABSTRACT--"Intranasal absorption of physostigmine and arecoline." J Pharm Sci 1991 Aug; 80(8):750-1					
		ABSTRACT--"A comparative evaluation of two transdermal nitroglycerin delivery systems: Nitro-Dur versus Transderm-Nitro. The Collaborative Investigation Group." Clin Ther 1991 Sep-Oct; 13(5): 545-9					
		ABSTRACT--"Pharmacokinetics and bioavailability of papaverine HCl following intravenous, peroral, rectal, vaginal, topical and buccal administration in beagle dogs." Biopharm Drug Dispos 1991 Oct; 12(7): 537-46					

[illegible]

with MPEP 609; draw line through  
tion.